Ciencias de la vida y de la materia Oncología personalizada de precisión

Manuel Hidalgo: "Nuevos abordajes terapéuticos en cáncer de páncreas"

21/03/2019

Descripción
Manuel Hidalgo, M.D., Ph.D., is director of the Leon V. and Marilyn L. Rosenberg Clinical Cancer Center, chief of the Division of Hematology–Oncology, and co-director of the Pancreatic Cancer Research Program at Beth Israel Deaconess Medical Center (BIDMC). He is also a professor of medicine at Harvard Medical School.Dr. Hidalgo received his M.D. from the University of Navarra and his Ph.D. from the University Autonoma of Madrid. He completed a fellowship in anticancer drug development at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo joined Johns Hopkins University School of Medicine as an associate professor and in 2003, became co-director of its Gastrointestinal Cancer Program. A native of Spain, Dr. Hidalgo came to BIDMC in 2015 from the Centro Nacional de Investigaciones Oncológicas (Spanish National Cancer Center) where he served as director of the Clinical Research Program and vice director of Translational Research. An internationally respected oncologist, Dr. Hidalgo is a world leader in the testing and development of new agents for pancreatic and other solid tumor cancers. He oversees all BIDMC clinical cancer programs.Dr.Hidalgo is a founder of the Pancreatic Cancer Research Team (PCRT), a private nonprofit cooperative group dedicated to rapid drug development in pancreatic cancer. He is member of the Science Committee of Cancer Research UK and Special Conferences Committee of the American Association of Cancer Research. Dr. Hidalgo is scientific editor of Cancer Discovery.
"La Fundación Ramón Areces no se hace responsable de las opiniones, comentarios o manifestaciones realizados por las personas que participan en sus actividades."

Descripción

Manuel Hidalgo, M.D., Ph.D., is director of the Leon V. and Marilyn L. Rosenberg Clinical Cancer Center, chief of the Division of Hematology–Oncology, and co-director of the Pancreatic Cancer Research Program at Beth Israel Deaconess Medical Center (BIDMC). He is also a professor of medicine at Harvard Medical School.Dr. Hidalgo received his M.D. from the University of Navarra and his Ph.D. from the University Autonoma of Madrid. He completed a fellowship in anticancer drug development at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo joined Johns Hopkins University School of Medicine as an associate professor and in 2003, became co-director of its Gastrointestinal Cancer Program. A native of Spain, Dr. Hidalgo came to BIDMC in 2015 from the Centro Nacional de Investigaciones Oncológicas (Spanish National Cancer Center) where he served as director of the Clinical Research Program and vice director of Translational Research. An internationally respected oncologist, Dr. Hidalgo is a world leader in the testing and development of new agents for pancreatic and other solid tumor cancers. He oversees all BIDMC clinical cancer programs.Dr.Hidalgo is a founder of the Pancreatic Cancer Research Team (PCRT), a private nonprofit cooperative group dedicated to rapid drug development in pancreatic cancer. He is member of the Science Committee of Cancer Research UK and Special Conferences Committee of the American Association of Cancer Research. Dr. Hidalgo is scientific editor of Cancer Discovery.

"La Fundación Ramón Areces no se hace responsable de las opiniones, comentarios o manifestaciones realizados por las personas que participan en sus actividades."

Vídeos
Ciencias de la vida y de la materia Oncología personalizada de precisión

Eduardo Díaz Rubio: "Lección Magistral: Estrategias de tratamiento en oncología: una perspectiva histórica"

21/03/2019

02carlosarteaga.mp4

Rafael Rosell: "Nuevas dianas terapéuticas en cáncer de pulmón"

21/03/2019

Patrick Tan: "Alteraciones epigenómicas en cánceres endémicos en Asia"

21/03/2019

Manuel Hidalgo: "Nuevos abordajes terapéuticos en cáncer de páncreas"

21/03/2019

Florian Markowetz: "Procesos mutacionales que modulan el número de copias de los genomas del cáncer"

21/03/2019

Santiago Ramón y Cajal: "Heterogeneidad intratumoral: cómo identificarla"

21/03/2019

Pier Paolo Pandolfi: "Reactivación de supresores tumorales en la prevención y terapia del cáncer"

21/03/2019

Enzo Medico: "Oncogenómica y modelos preclínicos derivados del paciente para la medicina de precisión del cáncer colorrectal"

21/03/2019

Ignacio Melero: "La búsqueda de eficacia y de biomarcadores en inmuno-oncología"

21/03/2019

Eric Aboagye: "Imagen molecular y radiómica en la investigación del cáncer: aplicaciones a la oncología de precisión"

21/03/2019

Felipe Calvo: "Radioterapia en la oncología de precisión"

21/03/2019

José Martínez Olmos: "La oncología personalizada de precisión en el Sistema Nacional de Salud"

21/03/2019

Fernando Bandrés: "Consideraciones éticas y legales en la medicina de precisión"

21/03/2019

Paul Workman: "Futuro y sostenibilidad de la investigación en oncología de precisión"

21/03/2019